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ORIGINAL ARTICLE
Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide
derivatives
Francesco Saccolitia, Gabriella Angiullib, Giovanni Pupoa, Luca Pescatoria, Valentina Noemi Madiaa,
Antonella Messorea, Gianni Colottib, Annarita Fiorillob, Luigi Scipionea , Marina Gramicciac, Trentina Di Muccioc,
Roberto Di Santoa , Roberta Costia† and Andrea Ilarib†
aIstituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Universita di Roma, Roma, Italia;
bIstituto di Biologia e Patologia Molecolari – CNR, and Dipartimento di Scienze Biochimiche, “Sapienza” Universita di Roma, Roma, Italia;
cDipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanita, Roma, Italia
ABSTRACT
The study presented here aimed at identifying a new class of compounds acting against Leishmania para-
sites, the causative agent of Leishmaniasis. For this purpose, the thioether derivatives of our in-house
library have been evaluated in whole-cell screening assays in order to determine their in vitro activity
against Leishmania protozoan. Among them, promising results have been achieved with compound RDS
777 (6-(sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine) (IC50¼29.43mM), which is able to impair the
mechanism of the parasite defence against the reactive oxygen species by inhibiting the trypanothione
reductase (TR) with high efficiency (Ki 0.25± 0.18mM). The X-ray structure of L. infantum TR in complex
with RDS 777 disclosed the mechanism of action of this compound that binds to the catalytic site and
engages in hydrogen bonds the residues more involved in the catalysis, namely Glu466', Cys57 and Cys52,
thereby inhibiting the trypanothione binding and avoiding its reduction.
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Introduction
The parasitic protozoan Leishmania, is the causative agent of
Leishmaniasis, a neglected tropical disease throughout the world.
Human Leishmaniasis consists of the following three major clinical
forms: visceral Leishmaniasis (VL), which is fatal if left untreated,
cutaneous Leishmaniasis, which can heal spontaneously but leaves
disfiguring scars, and mucocutaneous Leishmaniasis, which is not
self-healing and can be potentially fatal. VL causes an estimated
60 000 deaths annually (a rate surpassed among parasitic diseases
only by malaria)1,2. Leishmania, together with other protozoan
pathogens, that is, all species of Trypanosoma, belongs to the
Trypanosomatidae family. The therapy of such infections repre-
sents a neglected area of research and drug development.
Nowadays, treatment of these diseases is unsatisfactory in terms
of safety and efficacy, which sharply contrasts with the therapeutic
need in terms of people at risk, number of affected patients and
associated fatalities. This discrepancy is primarily due to the distri-
bution of these infections in tropical and subtropical poor coun-
tries that do not represent an attractive market for pharmaceutical
companies and have limited research capacities and public health
infrastructure. As a consequence, efficacious new drugs have not
been developed yet, and the available ones still comprise the
highly toxic antimony-containing compounds (i.e. glucantime and
pentostam). For this reason, there is an urgent need to find new
and more affordable drug-targeting protein essential for the para-
site survival but absent in the human host. Instead of the
mammalian redox defence machinery based on glutathione, the
trypanosomatid parasites possess trypanothione as the main
defending system against oxidative damage. Trypanothione,
[N1,N8-bis(glutathionyl)spermidine] (TS2), which is synthesized by
trypanothione synthetase (TryS) and reduced to T(SH)2 by the try-
panothione reductase (TR), is used by the couple tryparedoxin/try-
paredoxin peroxidase I (TXN/TXNPx) to neutralize the hydrogen
peroxide produced by the macrophages during the infection3,4. All
attempts to obtain a TR-null mutant in Leishmania (L.) donovani
failed and mutants, displaying a partial trisomy of TR locus, where
two TR alleles were disrupted by gene targeting, show attenuated
infectivity and decreased ability to survive within the macro-
phages5. Thus, due to the essential role played by TR in trypano-
somatids and its absence in the human host, trypanothione
reductase represents an attractive target for the development of
new potential drugs. The crystal structure of L. infantum TR has
recently been solved6 and has been shown to be very similar to
the structure of other trypanosomatid TR solved so far, that is, TR
from Chritidia (C.) fasciculata and from T. cruzi. TR is a homodimer
in which each subunit is formed by three domains: the interface
domain (361–488), the NADPH-binding domain (residues 161–289)
and the FAD-binding domain (residues 1–160 and 289–360). The
trypanothione-binding site is placed in a big cavity at the interface
between the two domains formed by the residues of the FAD-
binding site of one domain and the residues of the interface
domain of the twofold symmetry related subunit. The trypano-
thione is reduced by NADPH in a TR-catalyzed reaction with the
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following mechanism: the two NADPH electrons are transferred via
FAD to the Cys52-Cys57 disulfide bridge. When TS2 binds to the
protein, Cys52, deprotonated by the couple His4610-Glu4660,
attacks nucleophilically the trypanothione disulfide bridge with
the formation of a mixed disulfide bridge and finally, the attack of
the second protein cysteine (Cys57) on Cys52 produces the
reduced substrate. Baiocco et al. have shown that one of the
mechanisms of action of the antimonial drugs is the inhibition of
TR activity6. Sb(III) is able to inhibit TR (Ki ¼1.5mM), thereby killing
the Leishmania parasites. The structure of the Sb(III)–TR complex
shows that Sb(III) inhibits TR catalytic activity by binding to the
residues involved in catalysis, namely Cys52, Cys57 and His4610.
Several metals, such as Terpyridine platinum (II) complexes, gold
(I) derivatives and silver polypyridyl complexes, can be effective
against Leishmania spp.6. The X-ray structures of the Ag(I)- and
Au(I)-TR from L. infantum disclosed that all the metals that are
Lewis soft acids can bind to the two TR catalytic cysteines, thereby
inhibiting TR activity with a mechanism similar to that described
for Sb(III)7,8. Several organic compounds, such as acridines, 2- and
3-substituted 1,4-naphthoquinone derivatives, peptides and anil-
ine-based diarylsulfides, were designed on the basis of TR crystal
structure, as specific TR inhibitors9. Spinks et al. tested 62 000
compounds on T. brucei TR using a high-throughput screening
method based on the classical TR enzymatic assay coupled to the
DTNB (5,50-dithiobis-(2-nitrobenzoic acid)) reduction followed at
405 nm. They identified two series of compounds, based on quin-
oline and pyrimidopyridazine scaffolds, showing good selectivity
over the human homolog glutathione reductase (GR) and able to
inhibit TR in the micromolar range10,11.
In spite of various efforts to discover potent TR inhibitors that
did not block the closest mammalian homolog, glutathione reduc-
tase (GR), only a small number of compounds have been found to
have good anti-parasitic activity. An explanation was given by the
studies on conditioned TR knockout in T. brucei where it was dem-
onstrated that only the parasites with a TR wild-type activity lower
than 10% are unable to grow and infect mice5. For this reason, TR
should be inhibited at submicromolar range to prevent parasite
growth due to the endogenous substrate accumulation, which may
displace a competitive inhibitor with low affinity. In this framework,
our studies aimed at identifying a new class of compounds acting
against Leishmania parasites in submicromolar range. We evaluated
our in-house library of compounds previously synthesized and
endowed with different biological activities. In particular, our in-
house diaryl sulfide derivatives, previously synthesized as anti-HIV
agents12,13, have been evaluated in whole-cell screening assays for
determining their in vitro activity against Leishmania parasites.
Among them, promising results have been achieved with com-
pound RDS 777, which is able to inhibit the promastigotes growth
by binding with high affinity to the catalytic site of TR.
Materials and methods
Chemistry
Compound RDS 777 was synthesized as previously described in the
literature13; however, we decided to modify the second reaction
step applying a modified Buchwald-Hartwig C-S cross coupling reac-
tion14, as depicted in Scheme 1, in order to avoid the use of thio-
phenol potassium salt (difficult to handle) and reduce the reaction
time required, in spite of its reduced yield. Melting point (C),
recrystallization solvent, yield (%), chromatographic system, IR, 1H-
NMR, formula, Mr and analyzed elements for derivatives RDS 738
and RDS 777 are described in literature12,13. All compound samples
used for biological evaluation were determined to be 99% pure as
determined by elemental analysis.
6-(Sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine (RDS 777)
Compound RDS 738 (1 g; 4.96mmol) was added to a well-stirred
solution of Pd2(dba)3 (45.42mg; 49.6mmol), DPPF (55.28mg;
99.18 mmol), DIPEA (0.95ml; 5.45mmol) and 3-chlorobenzenthiol
(0.576ml; 4.96mmol) in anhydrous DMF (7.5ml) at room tempera-
ture. The solution was stirred under reflux for 6.5 h; the mixture
was cooled to room temperature, treated with water (50ml) and
extracted with chloroform (3 50ml). The collected extracts were
washed with brine (3 100ml) and dried. Removal of the solvent
furnished crude residue that was purified by CC (SiO2; n-hexane:
acetone 5:1), yielding RDS 777 (1.05 g, 68,33%) as a white-yellow
solid.
In vitro experiments: inhibition of promastigote growth
Promastigote (the extracellular stage of the Leishmania life cycle)
growth inhibition was evaluated using L. infantum strain (MHOM/
TN/80/IPT1). To estimate the 50% inhibitory concentration (IC50),
the MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium brom-
ide) micromethod15 was used throughout the experiments with
modification. Promastigotes were grown in Schneider’s Drosophila
medium (SIGMA) containing 10% fetal calf serum (FCS) (GIBCO-
BRL) and 2% gentamicin (50mg/l) (Sigma) at 22 C. Parasites were
adjusted to 1 106 parasites/ml, and 200 ll of suspension was
seeded in triplicate in 96-well flat-bottom microplates and incu-
bated with varying concentrations of RDS 777 compound from
stock solution in DMSO: 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25,
0.125, 0.062, 0.031 mM. Amphotericin B (Euroclone) (AmB) was
used as control at various concentrations: 8, 4, 2, 1, 0.5, 0.25,
0.125, 0.062mM . A DMSO control was assayed in parallel with the
concentration of DMSO never exceeding 1%. Each experiment was
done in triplicate for each drug concentration and two independ-
ent experiments were performed. After 72 h of incubation, 30ll of
MTT was added to each well and plates were further incubated
for 2 h. The absorbance at 550 nm was measured with a 96-well
scanner. Antileishmanial activity was expressed as a percentage of
the reduction in the number of live parasites compared to the
control (non-treated parasites). In addition, the promastigote vital-
ity was followed by microscopic observation after 72 h. Results
were analyzed by GraphPad Prism 3 (San Diego, CA).
Enzymatic assay
L. infantum TR was cloned and purified as previously described6,16.
Enzyme inhibition assays were carried out at 25 C using a diode
array Hewlett–Packard HP8452A spectrophotometer. The solution
Scheme 1. Synthesis of RDS 777. (i) sec-BuOH, Na, reflux, 4 h, 50% 12,13; (ii) 3-chlorothiophenol, Pd2(dba)3, DPPF, DIPEA, DMF, reflux, 6.5 h, 68.33%.
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containing TR 40 nM, TS2 (75 mM, 100mM, 200 mM, 400mM) and
RDS777 (50 nM, 100 nM, 250 nM, 500 nM, 1 mM, 5mM, 10mM) were
allowed to equilibrate for 2min in a quartz cuvette. Assays were
initiated by the addition of NADPH 40 mM and the absorbance
decrease at 340 nm, which indicates the oxidation of NADPH, was
followed. The concentrations of NADPH was calculated using
the molar extinction coefficient e¼ 6222 /M/cm at 340 nm.
Trypanothione disulfide (Bachem) and NADPH (Sigma) were used
for the experiments.
X-ray structure determination
Crystallization of TR from L. infantum were carried out as previ-
ously reported6,16. The crystals grew at a controlled temperature
of 294 K, reaching dimension of 0.3mm 0.3mm 0.2mm in
about 7 days. Crystals of the native oxidized TR were soaked for
1 h using a stabilizing solution containing 1.5 M ammonium sul-
fate, 0.1 M Tris pH 8.5 and 2mM inhibitor. Crystals were cryo-pro-
tected in a solution containing 2.0 M sodium malonate. Then, the
crystals were flash-frozen by quick submersion into liquid nitrogen
for transport to a synchrotron radiation source.
Single wavelength data sets (k¼ 0.918 Å) were collected at the
beamline BL 14–1 at the Synchrotron Radiation Source BESSY17,
Berlin, Germany, using a CCD detector at a temperature of 100 K.
The data sets were processed and scaled with XDS18. The crystals
belong to the P41 space group with the following cell dimensions:
a¼ 102.5 Å, b¼ 102.5 Å, c¼ 192Å. Crystal parameters and complete
data collection statistics are reported in Table 1. The structures of
L. infantum TR in complex with RDS777 were solved by molecular
replacement using as search model the native TR (pdb code
2JK6)6 with the program Molrep19. Refinement was performed
using the program REFMAC520 and model building was carried
out using the program COOT21. The structure of TR in complex
with RDS777 was refined to a final free R value of 23.3% for all
resolution shells (50–3.5 Å), calculated using the working set
reflections (23 650) and Free R value, calculated using the test set
reflections (1621), of 35.6%. The final model is a dimer containing
974 residues (486 for monomer A and 487 for monomer B), two
FAD molecules, one sulfate molecule and seven RDS777 molecules
(three in the monomer A and four in the monomer B). The most
favored regions of the Ramachandran plot contains 92.0% of resi-
dues, the allowed regions contain the 8.0% of residues. The X-ray
structure has been deposited in the protein data bank with the
PDB code 5EBK.
Results and discussion
Activity against Leishmania promastigotes assays
Stump et al. already have shown that some diaryl sulfides are able
to inhibit T. brucei TR, thereby killing the protozoan (some of
them displayed an IC50 in the micromolar range)
22.
On this basis, we evaluated our in-house library of diaryl sulfide
compounds previously synthesized and endowed with different
biological activities against Leishmania infantum promastigotes. In
particular, our in-house diaryl sulfide derivatives, previously syn-
thesized as anti-HIV agents12,13, have been evaluated in whole cell
screening assays for determining their in vitro activity against
Leishmania parasites. Among them, only RDS 777 shows a signifi-
cant activity against promastigotes.
RDS 777 induced a dose-dependent antiproliferative effect on
L. infantum promastigotes. Seventy-two hours after treatment,
256–128 mM concentrations of RDS 777 induced 100% promasti-
gote mortality, whereas lower drug concentrations induced a
dose-dependent anti-proliferative effect on L. infantum promasti-
gotes. IC50 deduced from the dose-response curve was
29.43 ± 1.34mM (95% CI: 15.94–54.34), (the deduced IC50 of AmB
was 0.52 ± 1.59 mM; 95% CI: 0.18–1.45) (Figure 1). No effect on pro-
mastigotes growth was observed by the presence of up to 1%
DMSO in the culture medium. The calculated IC50 is of the same
order of magnitude of that calculated for compound 1 (4-((1–(4-
ethylphenyl)-2-methyl-5–(4-(methylthio)phenyl)-1H-pyrrol-3-yl)methyl)
thiomorpholine), an azole-based compound that has been shown to
be able to bind to the trypanothione-binding cavity, against
Leishmania donovani (13.77mM)23.
Enzymatic assay
Steady-state kinetic experiments were carried out at various
concentration of TS2 and inhibitor and at a fixed NADPH
Table 1. Crystal parameters, data collection statistics and refinement statistics of
RDS777–TR complex
Space group P41
Unit cell parameters
a (Å) 102.5
b (Å) 102.5
c (Å) 192
Number of molecule in the asymmetric unit 2
Wilson plot B factor (Å2) 95.5
Data statistics
Resolution range 3.5–48 (3.5–3.7)
Unique reflections 24 914 (3949)
Completeness 99.6 (98.1)
Redundancy 5.12 (5.04)
Rmerge(%) 23 (117)
CC1/2 99 (75.1)
I/r(I) 8.2 (1.7)
Structure refinement
Resolution range 3.5–48 (3.5–3.6)
Reflection in bins 23 650 (1666)
Rcrys (%) 21 (36)
Rfree (%) 23 (36)
Rms bonds (Å) 0.009
Rms angle () 1.4
Ramachandran plot
Residues in core region (%) 92
Residues in allowed region (%) 8
Values in parentheses are for the high-resolution shell.Rmerge ¼
P
hkl
P
I Ii hklð Þ  I hklð Þj j =P hklPi Ii hklð Þ, where Ii(hkl) is the ith
observation of the reflection (hkl) and I(hkl) is the mean intensity of the (hkl)
reflection.
Figure 1. % Inhibition calculated on L. infantum promastigote stage after treat-
ment with various concentrations of RDS777 and reference drug Amphothericin B
(AmB). The data are expressed as mean± standard error of two independent
experiments.
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concentration (40mM). After starting the reaction by the addition
of NADPH, the absorbance decrease at 340 nm, indicating the oxi-
dation of NADPH, was measured. As shown from Figure 2, RDS
777 inhibits competitively the binding of trypanothione to TR.
Each line in the Dixon plot (Figure 2) represents linear regression
analysis of reciprocal of average simulated rates of trypanothione
reduction for different substrate concentrations as a function of
inhibitor concentration. The KM and kcat of TR used for the Ki cal-
culation are 23 ± 1mM and 11.4 ± 0.3/s respectively23. The value of
Ki calculated from the Dixon plot analysis is 0.25 ± 0.18mM six
times lower than that of Sb(III) (1.5mM) the active form of antimo-
nials the most used drug against Leishmaniasis calculated by
Baiocco et al6 and more than 18 times lower than is that of com-
pound 1 (4.6 ± 2.5 mM)23.
The RDS 777 Ki value (0.25 ± 0.18mM) is two order of magni-
tude lower than the IC50 deduced from the dose-response curve
(29.43 ± 1.34 mM). Numerous specific and efficient tripanosomatids
TR inhibitors have been found to have modest effect on the
parasites grown. A partial explanation was provided by Krieger
et al. who produced conditioned TR knockout in T. brucei24. They
have shown that the redox metabolism of the parasite was
affected only when TR was titrated down to less than 5% of
normal.
X-ray crystal structure of TR in complex with RDS 777
Stump et al.22 have already shown the ability of diarylsulfide deriv-
atives to bind T. cruzi TR and tentatively proposed a modelling-
based binding mode for this class of compounds.
In order to study the mechanism of inhibition exerted by this
compound and determine the binding mode of the diaryldisulfide
derivatives, we solved the X-ray structure of L. infantum TR in its
oxidized state in complex with RDS 777 (LiTR-777) at 3.5 Å reso-
lution (Figure 3). Apart from few cases, such as previously reported
azole-based compounds23, no binding mode of any competitive
Leishmania TR inhibitor has been deciphered by protein crystallog-
raphy to date; thus, the development of novel TR inhibitors has
been based on molecular dynamics simulations without X-ray
study confirmation. In this sense, our crystallographic study gave
us a clear and specific insight of RDS 777-binding mode, highlight-
ing that our compound is involved in some peculiar, well-defined
interactions into TR catalytic site.
The X-ray structure of LiTR-777 is identical to the TR-oxidized
apo-form. The functional dimer is made of two identical subunits
related by a twofold axis (the superimposition between the two
monomers A and B yields a rmsd of 0.18 Å). Each monomer con-
tains a FAD molecule. The monomer A binds three RDS 777 mole-
cules, whereas the monomer B binds four RDS 777 molecules. RDS
777 b and c are bound in both monomers to the NADPH-binding
site, whereas the RDS 777 a in the monomer A and a and d in
monomer B are bound to the trypanothione-binding site
(Figure 3). The RDS 777 in position a are bound in similar way in
the two monomers (Figure 4(A) and (B)).
Due to the presence of several nonpolar aminoacids within the
catalytic site, RDS 777 in position a interacts with the hydrophobic
Val53 and Val58 and, furthermore, it is hydrogen bound to the
Figure 3. Overall fold of TR in complex with RDS 777. RDS777 is represented as CPK and colored orange and the FAD molecules is represented as sticks and colored
in yellow. The seven RDS777 molecules bound to the TR protein are indicated with the a–d letters.
Figure 2. Dixon plot of TR inhibition by RDS777: open circles [TS2]¼ 75lM; filled
squares [TS2]¼ 100lM; filled diamonds [TS2]¼ 200lM and open squares
[TS2]¼ 400lM.
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residues more involved in the catalysis, namely His 4610, Glu4660,
Cys57, Cys52 and Glu4670 (Figure 5(A) and 5(B)). In particular, RDS
777 in position a interacts, through the aniline moiety, with the
acidic residue Glu4660, while the arylsulfide moiety localizes near
the hydrophobic Val53 and Val58 and close to Tyr110 a residue
important for the trypanothione correct positioning in the cavity23.
Moreover, as shown in the Figure 5(A), the chloride atom of the
benzyl chloride moiety forms electrostatic interactions with the
sulfur atoms of the two catalytic cysteines (Cys 52 and Cys 57)
forming a disulfide bridge. This binding mode is peculiar of our
diarylsulfide inhibitor, which, however, enlightens an alternative
interaction mode different from the other simulated ones previ-
ously described in literature. In particular, the diarylsulfide deriva-
tive (3-({5-Chloro-2-[(40-methylbiphenyl-4-yl)thio]phenyl}amino)-N-
(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-ammonium chloride))
modeled by Stump et al. in the trypanothione-binding site
accommodates in the cavity in a completely different manner. In
their model, the diarylsulfide moiety is positioned close to the so-
called “mepacrine”-binding site distant from the two catalytic
cysteines.
In the monomer B of LiTR-777 X-ray structure, an additional
molecule of RDS 777 binds to the trypanothione-binding site (mol-
ecule d). This additional molecule displays an occupancy lower
than 1 (0.8) and is placed close to the entrance of the trypano-
thione-binding site. The chloro benzyl moiety of the molecule d
forms a stacking interaction with the aniline moiety of the mol-
ecule a and a hydrogen bond with the Glu4670. As shown in
Figure 5(C), the binding mode of the diaryl sulfides differs from
that of the more bulky diphenyl pyrroles that are placed nearer
the entrance of the cavity and farther from the LiTR catalytic triad.
Conclusions
In order to identify novel anti-Leishmanian agents engaged with
good activity, we evaluated the antiprotozoan activity of our in-
house library of compounds. Among them, RDS 777 proved to be
Figure 4. Electronic density map of the RDS777–TR complex active site. (A) 2Fo-Fc map of the monomer A. (B) 2Fo-Fc map of the monomer B. RDS 777 and the resi-
dues interacting with the compounds are represented as sticks. The 2Fo-Fc map is colored blue and contoured at 1 r.
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one of the most promising derivative in whole-cell screening
assay, showing IC50 value in the micromolar range. Furthermore, it
demonstrates high affinity for trypanothione reductase of L. infan-
tum, confirming its mechanism of action as inhibitor of the afore-
mentioned enzyme involved in the protozoan defense from
oxidative damage. The X-ray structure of LiTR in complex with
RDS 777 has been solved, enlightening the binding mode of our
diarylsulfide derivative in the catalytic site of the protozoan
enzyme. This structure shows that RDS 777 binds to the residues
more involved in the catalysis, thereby impairing the catalytic
activity of TR.
Nevertheless, inhibiting homolog trypanothione reductase
enzymes, RDS 777 could display interesting activities also against
other protozoans belonging to the Trypanosomatidae family and,
thus, it could represent an useful tool for the treatment of other
related neglected diseases, such as Chagas’ disease (caused by
T. cruzi) and African sleeping sickness (caused by T. brucei), for
which, nowadays, no effective and safe therapy is available.
These data provide important insight that could be very helpful
for future development of a novel class of anti-protozoan inhibi-
tors endowed with focused structural modifications in order to
increase affinity and potency against protozoan target.
Acknowledgements
We gratefully acknowledge the Helmholtz-Zentrum Berlin –
Electron storage ring BESSY II for providing synchrotron radiation
at beamline BL14–1. from the European Community's Seventh
Framework Program (FP7/2007–2013) under BioStruct-X (grant
agreement no. 283570) and Bag Project 1223, CNCCS CNR
(National Collection of Chemical Compounds and Screening
Center 2015) to AI.
Disclosure statement
The authors report no conflicts of interest. The authors alone are
responsible for the content and writing of this article.
Funding
CNCCS CNR (National Collection of Chemical Compounds and
Screening Center 2015) [B56G15001140005].
ORCiD
Luigi Scipione http://orcid.org/0000-0002-2006-7005
Roberto Di Santo http://orcid.org/0000-0002-4279-7666
Roberta Costi http://orcid.org/0000-0002-1314-9029
Andrea Ilari http://orcid.org/0000-0002-7754-399X
References
1. Desjeux P. Leishmaniasis: current situation and new perspec-
tives. Comp Immunol Microbiol Infect Dis 2004;27:305–18.
Figure 5. Blow up of the active site of TR. (A) Interaction map of RDS 777 in the TR-active site of monomer A. The residues interacting with RDS 777 are indicated
and represented as sticks. (B) Interaction map of the a and d RDS777 molecules in the TR-active site of monomer B. The residues interacting with RDS 777 are indi-
cated and represented as sticks. (C) Superimposition between the compound1–TR structure (PDB code 4APN) and RDS777–TR structure. The two molecules of com-
pound 1 (4-((1–(4-ethylphenyl)-2-methyl-5–(4-(methylthio) phenyl)-1H-pyrrol-3 yl)methyl)thiomorpholine), RDS 777 and FAD are represented as sticks.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 309
2. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases
of the Middle East and North Africa: review of their preva-
lence, distribution, and opportunities for control. PLoS
Neglected Trop Dis [Online] 2012;6:e1475. Available from:
http://journals.plos.org/plosntds/article?id¼10.1371/journal.pntd.
0001475.
3. Colotti G, Baiocco P, Fiorillo A, et al. Structural insights into
the enzymes of the trypanothione pathway: targets for anti-
leishmaniasis drugs. Future Med Chem 2013;5:1861–75.
4. Fiorillo A, Colotti G, Boffi A, et al. The crystal structures of
the tryparedoxin-tryparedoxin peroxidase couple unveil the
structural determinants of Leishmania detoxification path-
way. PLoS Negl Trop Dis [Online] 2012;6:e1781. Available
from: http://journals.plos.org/plosntds/article?id¼10.1371%2F
journal.pntd.0001781.
5. Dumas C, Ouellette M, Tovar J, et al. Disruption of the trypa-
nothione reductase gene of Leishmania decreases its ability
to survive oxidative stress in macrophages. EMBO J 1997;16:
2590–8.
6. Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis
of antimony treatment in leishmaniasis. J Med Chem
2009;52:2603–12.
7. Ilari A, Baiocco P, Messori L, et al. A gold-containing drug
against parasitic polyamine metabolism: the X-ray structure
of trypanothione reductase from Leishmania infantum in
complex with auranofin reveals a dual mechanism of
enzyme inhibition. Amino Acids 2012;42:803–11.
8. Baiocco P, Ilari A, Ceci P, et al. Inhibitory effect of silver nano-
particles on trypanothione reductase activity and Leishmania
infantum proliferation. ACS Med Chem Lett 2010;2:230–3.
9. Ilari A, Fiorillo A, Baiocco P, et al. Targeting polyamine
metabolism for finding new drugs against leishmaniasis: a
review. Mini Rev Med Chem 2015;15:243–52.
10. Spinks D, Torrie LS, Thompson S, et al. Design, synthesis and
biological evaluation of Trypanosoma brucei trypanothione
synthetase inhibitors. ChemMedChem 2012;7:95–106.
11. Spinks D, Shanks EJ, Cleghorn LA, et al. Investigation of
trypanothione reductase as a drug target in Trypanosoma
brucei. ChemMedChem 2009;4:2060–9.
12. Massa S, Di Santo R, Costi R, et al. Synthesis of novel HEPT ana-
logues with anti-HIV-1 activity. Med Chem Res 1994;4:554–62.
13. Costi R, Di Santo R, Artico M, et al. Structure-activity relation-
ship studies on potential non-nucleoside DABO-like inhibi-
tors of HIV-1 reverse transcriptase. Antivir Chem Chemother
2000;11:117–33.
14. Okauchi T, Kuramoto K, Kitamura M. Facile preparation of
aryl sulfides using palladium catalysis under mild conditions.
Synlett 2010;2891–4.
15. Sereno D, Lemesre JL. Use of an enzymatic micromethod to
quantify amastigote stage of Leishmania amazonensis
in vitro. Parasitol Res 1997;83:401–3.
16. Baiocco P, Franceschini S, Ilari A, Colotti G. Trypanothione
reductase from Leishmania infantum: cloning, expression,
purification, crystallization and preliminary X-ray data ana-
lysis. Protein Pept Lett 2009;16:196–200.
17. Mueller U, Darowski N, Fuchs MR, et al. Facilities for macro-
molecular crystallography at the Helmholtz-Zentrum Berlin.
J Synchrotron Radiat 2012;19:442–9.
18. Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr 2010;66:
125–32.
19. Vagin AA, Teplyakov A. Molecular replacement with
MOLREP. Acta Crystallogr D Biol Crystallogr 2010;66:22–5.
20. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macro-
molecular structures by the maximum-likelihood method.
Acta Crystallogr D Biol Crystallogr 1997;53:240–55.
21. Emsley P, Cowtan K. Coot: model-building tools for molecu-
lar graphics. Acta Crystallogr D Biol Crystallogr 2004;60:
2126–32.
22. Stump B, Eberle C, Kaiser M, et al. Diaryl sulfide-based inhibi-
tors of trypanothione reductase: inhibition potency, revised
binding mode and antiprotozoal activities. Org Biomol Chem
2008;6:3935–47.
23. Baiocco P, Poce G, Alfonso S, et al. Inhibition of Leishmania
infantum Trypanothione Reductase by Azole-Based
Compounds: a Comparative Analysis with Its Physiological
Substrate by X-ray Crystallography. ChemMedChem 2013;8:
1175–83.
24. Krieger S, Schwarz W, Ariyanayagam MR, et al.
Trypanosomes lacking trypanothione reductase are avirulent
and show increased sensitivity to oxidative stress. Mol.
Microbiol 2000;35:542–52.
310 F. SACCOLITI ET AL.
